Requirement for IL-2 and Large Numbers of 14C3 Cells to Prevent Rejection
| Exp . | 14C3 Cells . | IL-2 Dose (U/d) . | IL-2 Days . | Percent Donor Cells . | |
|---|---|---|---|---|---|
| T Cells . | Granulocytes . | ||||
| 1 | 20 × 106 | None | 0, 1, 0, 1, 0 | 3, 9, 3, 5, 10 | |
| 80 | 0-6 | 1, 48, 64, 1, 1 | 9, 86, 100, 8, 7 | ||
| 400 | 0-6 | 4, 1, 0, 1, 1 | 24, 9, 8, 11, 8 | ||
| 2,000 | 0-6 | 5, 15, 92, 58, 96 | 14, 62, 99, 92, 97 | ||
| 2 | 20 × 106 | 240 | 0-6 | 100, 1, 100, 100 | 98, 7, 92, 88 |
| 1,200 | 0-6 | 100, 99, 99, 100, 100 | 93, 64, 86, 93, 97 | ||
| 6,000 | 0-6 | 100, 99, 99, 100, 100 | 97, 59, 53, 93, 90 | ||
| 3 | None | 30,000 | 0-13 | 0, 0, 0, 0, 0 | 2, 4, 5, 3, 3 |
| 5 × 106 | 30,000 | 0-13 | 0, 0, 0, 0, 0 | 6, 6, 4, 3, 4 | |
| 10 × 106 | 30,000 | 0-13 | 0, 0, 0, 0, 47 | 1, 4, 5, 5, 95 | |
| 20 × 106 | 30,000 | 0-13 | 31, 11, 97, 0, 100 | 77, 87, 95, 8, 98 | |
| Exp . | 14C3 Cells . | IL-2 Dose (U/d) . | IL-2 Days . | Percent Donor Cells . | |
|---|---|---|---|---|---|
| T Cells . | Granulocytes . | ||||
| 1 | 20 × 106 | None | 0, 1, 0, 1, 0 | 3, 9, 3, 5, 10 | |
| 80 | 0-6 | 1, 48, 64, 1, 1 | 9, 86, 100, 8, 7 | ||
| 400 | 0-6 | 4, 1, 0, 1, 1 | 24, 9, 8, 11, 8 | ||
| 2,000 | 0-6 | 5, 15, 92, 58, 96 | 14, 62, 99, 92, 97 | ||
| 2 | 20 × 106 | 240 | 0-6 | 100, 1, 100, 100 | 98, 7, 92, 88 |
| 1,200 | 0-6 | 100, 99, 99, 100, 100 | 93, 64, 86, 93, 97 | ||
| 6,000 | 0-6 | 100, 99, 99, 100, 100 | 97, 59, 53, 93, 90 | ||
| 3 | None | 30,000 | 0-13 | 0, 0, 0, 0, 0 | 2, 4, 5, 3, 3 |
| 5 × 106 | 30,000 | 0-13 | 0, 0, 0, 0, 0 | 6, 6, 4, 3, 4 | |
| 10 × 106 | 30,000 | 0-13 | 0, 0, 0, 0, 47 | 1, 4, 5, 5, 95 | |
| 20 × 106 | 30,000 | 0-13 | 31, 11, 97, 0, 100 | 77, 87, 95, 8, 98 | |
Groups of five irradiated (800 cGy) CB6 recipients were transplanted with 5.0 × 106 T-cell–depleted B6C3 marrow cells with or without the indicated numbers of 14C3 cells added to the graft. Recipients were treated with IL-2 administered IP daily according to the indicated doses and schedules. The percent of donor T cells and granulocytes in the blood of survivors at 2 months after transplantation was determined by two-color staining with CD3 and H2KkDk-specific antibodies. Data indicate results for individual recipients. Three recipients in Experiment 1 (Exp 1) remained stably engrafted with donor-derived T cells and granulocytes when last tested on day 117 after transplantation. Thirteen of the 14 recipients in Exp 2 remained stably engrafted when last tested on day 92 after transplantation. Five of the 20 recipients in Exp 3 remained stably engrafted when last tested on day 102 after transplantation.